Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published
Guidance, NICE advice and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Last updated date
Last updated date
From date
To date
Apply date filters
Type
(
1 selected
)
Type
Guidance (35)
Guidance programme
(
1 selected
)
Guidance programme
Cancer service guidelines (1)
Clinical guidelines (3)
Diagnostics guidance (2)
Interventional procedures guidance (5)
Medical technologies guidance (1)
NICE guidelines (4)
Technology appraisal guidance (35)
Apply filters
Showing 1 to 35 of 35
Sort by
Date
Title
Apply sorting
breast cancer
Remove breast cancer filter
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Talazoparib for treating HER2-negative advanced
breast cancer
with germline BRCA mutations
TA952
21 February 2024
21 February 2024
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early
breast cancer
after chemotherapy
TA886
10 May 2023
10 May 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic
breast cancer
after 1 or more anti-HER2 treatments
TA862
1 February 2023
1 February 2023
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced
breast cancer
TA851
14 December 2022
14 December 2022
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced
breast cancer
after endocrine therapy
TA836
26 October 2022
26 October 2022
Sacituzumab govitecan for treating unresectable triple-negative advanced
breast cancer
after 2 or more therapies
TA819
17 August 2022
17 August 2022
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced
breast cancer
TA816
10 August 2022
10 August 2022
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early
breast cancer
at high risk of recurrence
TA810
20 July 2022
20 July 2022
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic
breast cancer
TA801
29 June 2022
29 June 2022
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced
breast cancer
after 2 or more anti-HER2 therapies
TA786
27 April 2022
27 April 2022
Olaparib for treating BRCA mutation-positive HER2-negative metastatic
breast cancer
after chemotherapy (terminated appraisal)
TA762
2 February 2022
2 February 2022
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced
breast cancer
after endocrine therapy
TA725
15 September 2021
15 September 2021
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic
breast cancer
after 2 or more anti-HER2 therapies
TA704
26 May 2021
26 May 2021
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced
breast cancer
after endocrine therapy
TA687
31 March 2021
31 March 2021
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative
breast cancer
TA639
1 July 2020
1 July 2020
Trastuzumab emtansine for adjuvant treatment of HER2-positive early
breast cancer
TA632
10 June 2020
10 June 2020
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage
breast cancer
after adjuvant trastuzumab
TA612
20 November 2019
20 November 2019
Pertuzumab for adjuvant treatment of HER2-positive early stage
breast cancer
TA569
20 March 2019
20 March 2019
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic
breast cancer
TA563
27 February 2019
27 February 2019
Eribulin for treating locally advanced or metastatic
breast cancer
after 1 chemotherapy regimen
TA515
28 March 2018
28 March 2018
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive
breast cancer
TA509
7 March 2018
7 March 2018
Intrabeam radiotherapy system for adjuvant treatment of early
breast cancer
TA501
31 January 2018
31 January 2018
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive
breast cancer
TA503
31 January 2018
31 January 2018
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic
breast cancer
TA495
20 December 2017
20 December 2017
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic
breast cancer
TA496
20 December 2017
20 December 2017
Trastuzumab emtansine for treating HER2-positive advanced
breast cancer
after trastuzumab and a taxane
TA458
19 July 2017
20 November 2017
Everolimus with exemestane for treating advanced
breast cancer
after endocrine therapy
TA421
21 December 2016
21 December 2016
Eribulin for treating locally advanced or metastatic
breast cancer
after 2 or more chemotherapy regimens
TA423
21 December 2016
21 December 2016
Pertuzumab for the neoadjuvant treatment of HER2-positive
breast cancer
TA424
21 December 2016
21 December 2016
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic
breast cancer
TA263
22 August 2012
22 August 2012
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive
breast cancer
that overexpresses HER2
TA257
27 June 2012
27 June 2012
Fulvestrant for the treatment of locally advanced or metastatic
breast cancer
TA239
14 December 2011
14 December 2011
Bevacizumab in combination with a taxane for the first-line treatment of metastatic
breast cancer
TA214
23 February 2011
23 February 2011
Gemcitabine for the treatment of metastatic
breast cancer
TA116
24 January 2007
24 January 2007
Guidance on the use of trastuzumab for the treatment of advanced
breast cancer
TA34
15 March 2002
15 March 2002
Current page
1
Page
1
of
1
Results per page
10
25
50
All
Back to top